Combinations of Therapeutic Agents for Treating Cancer

A method of preventing or treating a proliferative disease comprising a combination of:

• (a) a microtubule active agent;
• and
• (b) one or more pharmaceutically active agents selected from the group consisting of:
• i. an adenosine-kinase-inhibitor;
• ii. an adjuvant;
• iii. an adrenal cortex antagonist;
• iv. AKT pathway inhibitor;
• v. An alkylating agent;
• vi. an angiogenesis inhibitor;
• vii. an anti-androgen;
• viii. an anti-estrogen;
• ix. an anti-hypercalcemia agent;
• x. an antimetabolite;
• xi. an apoptosis inducer;
• xii. an aurora kinase inhibitor;
• xiii. a Bruton's Tyrosine Kinase (BTK) inhibitor;
• xiv. a calcineurin inhibitor;
• xv. a CaM kinase II inhibitor;
• xvi. a CD45 tyrosine phosphatase inhibitor;
• xvii. a CDC25 phosphatase inhibitor;
• xviii. a CHK kinase inhibitor;
• xix. a controlling agent for regulating genistein, olomucine and/or tyrphostins;
• xx. a cyclooxygenase inhibitor;
• xxi. a cRAF kinase inhibitor;
• xxii. a cyclin dependent kinase inhibitor;
• xxiii. a cysteine protease inhibitor;
• xxiv. a DNA intercalator;
• xxv. a DNA strand breaker;
• xxvi. an E3 Ligase inhibitor;
• xxvii. an endocrine hormone;
• xxviii. compounds targeting, decreasing or inhibiting the activity of the epidermal growth factor family;
• xxix. an EGFR, PDGFR tyrosine kinase inhibitor;
• xxx. a farnesyltransferase inhibitor;
• xxxi. a Flk-1 kinase inhibitor;
• xxxii. a Glycogen synthase kinase-3 (GSK3) inhibitor;
• xxxiii. a histone deacetylase (HDAC) inhibitor;
• xxxiv. a HSP90 inhibitor;
• xxxv. a I-kappa B-alpha kinase inhibitor (IKK);
• xxxvi. an insulin receptor tyrosine kinase inhibitor;
• xxxvii. a c-Jun N-terminal kinase (JNK) kinase inhibitor;
• xxxviii. a Mitogen-activated protein (MAP) kinase-inhibitor;
• xxxix. a MDM2 inhibitor;
• xl. a MEK inhibitor;
• xli. a matrix metalloproteinase inhibitor (MMP) inhibitor;
• xlii. a NGFR tyrosine-kinase-inhibitor;
• xliii. a p38 MAP kinase inhibitor, including a SAPK2/p38 kinase inhibitor;
• xliv. a p56 tyrosine kinase inhibitor;
• xlv. a PDGFR tyrosine kinase inhibitor;
• xlvi. a phosphatidylinositol 3-kinase inhibitor;
• xlvii. a phosphatase inhibitor;
• xlviii. a platinum agent;
• xlix. a protein phosphatase inhibitor, including a PP1 and PP2 inhibitor and a tyrosine phosphatase inhibitor;
• l. a PKC inhibitor and a PKC delta kinase inhibitor;
• li. a polyamine synthesis inhibitor;
• lii. a proteosome inhibitor;
• liii. a PTP1B inhibitor;
• liv. a protein tyrosine kinase inhibitor including a SRC family tyrosine kinase inhibitor;
• a Syk tyrosine kinase inhibitor;
• and a JAK-2 and/or JAK-3 tyrosine kinase inhibitor;
• lv. a retinoid;
• lvi. a RNA polymerase II elongation inhibitor;
• lvii. a serine/threonine kinase inhibitor;
• lviii. a sterol biosynthesis inhibitor;
• lix. a topoisomerase inhibitor;
• i. VEGFR tyrosine kinase inhibitor;
• and a mixture thereof.